The takeaway
Keros Therapeutics Inc shows a pronounced seasonal pattern over 6 years of data — strongest in November (+15.3%) and softest in May (−10.2%).
Right now
In July, the stock has risen 67% of years, averaging +3.1%, about +0.9 pts better than the S&P 500.
The full picture
Keros Therapeutics Inc's most dependable month has been November, higher in 4 of 6 years; May has been its least reliable, up just 17% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in November (+13.0 pts); it has trailed the market most in May (−10.9 pts).
“vs S&P” is Keros Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Keros Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, November has closed higher 60% of the time versus 67% across the last 6 years — the pattern is weakening.
Figures are the typical (median) November return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The year leans November's way without overwhelming the rest of it: the stock has closed higher in 4 of 6 Novembers, its most dependable month if not a dominant one.
A typical November brings +10.5%, a shade under the +15.3% average. That reliability comes with real swings, mind — even November ranges by 17.8% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: November has cleared the S&P 500 by +13.0 points above the index. Some of that is a strong month market-wide, mind — November rises for about 62% of stocks — so the tendency is real if not unique.
A few other months pull their weight: February, April, and July have also closed higher more often than not. At the other end of the calendar, May has been the soft spot — the weakest of 5 months that average a loss (−10.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in May, March, and June. Its roughest month on record was a −72.1% December in 2024 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, November's last five years slipping below its longer-run record.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (November), its worst (May), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (November, +15.3%) has run well ahead of its worst (May, −10.2%) — the heatmap above shows how steady that gap has been year to year.
November has been the strongest, averaging +15.3% and closing higher in 4 of 6 years since 2020.
It's the weakest, averaging −10.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade